Dyadic International Inc (DYAI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.34-7.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · DYAI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -72.0% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 12.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
DYAI — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-09-25
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. (a) On September 25, 2026, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the cont…
Why it matters: Nasdaq sent a new bid-price notice on September 25. Meeting its terms would keep the listing issue from worsening.
Worry ifA Nasdaq filing says DYAI met the notice terms by keeping its bid price at or above $1 for the required period.
Less concerning ifA Nasdaq filing says the company did not meet the notice terms, or received a delisting notice.
Why it matters: Proliant has begun selling Albufree DX. More products could add new sales tied to Dyadic's platform.
Supportive ifProliant announces commercial sales of Albufree TX or Albufree CGT, beyond the Albufree DX launch.
Worry ifA later company update says neither TX nor CGT has launched, or says the Albufree DX sales have stopped.
Why it matters: The next report can show whether product shipments, cash, and partner sales improved after Q2.
Watch forThe November 11 report shows revenue above $961,138 and cash above the June balance of $4,794,798.
Also watch forThe November 11 report shows revenue at or below $961,138 and cash at or below $4,794,798.
Why it matters: Q2 revenue slipped slightly from Q1. A rise would show that product sales and partner work are gaining ground.
Supportive ifQ3 revenue is above $961,138. Reported product sales or partner shipments contribute.
Worry ifQ3 revenue is at or below $961,138, or the company reports lower product sales and shipments.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$366 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $814 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,686 loss on $10,000 · 76.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cash was about $4.8 million in June, and the company raised about $2.9 million in August. It also reported doubt about funding operations for 12 months.
Worry ifQ3 cash, restricted cash, and investment securities are below $7.7 million. This is the June balance plus stated gross offering proceeds.
Less concerning ifQ3 cash, restricted cash, and investment securities are at or above $7.7 million. No new share or warrant sale is reported.